Accessibility Menu
 
Trevi Therapeutics logo

Trevi Therapeutics

(NASDAQ) TRVI

Current Price$14.14
Market Cap$2.01B
Since IPO (2019)+79%
5 Year+608%
1 Year+134%
1 Month-5%

Trevi Therapeutics Financials at a Glance

Market Cap

$2.01B

Revenue (TTM)

$0.00

Net Income (TTM)

$45.61M

EPS (TTM)

$-0.32

P/E Ratio

-43.68

Dividend

$0.00

Beta (Volatility)

0.81 (Low)

Price

$14.14

Volume

1,323,227.906

Open

$14.23

Previous Close

$14.13

Daily Range

$14.12 - $14.49

52-Week Range

$5.38 - $16.12

TRVI News

No articles available.

TRVI: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Trevi Therapeutics

Industry

Pharmaceuticals

Employees

34

CEO

Jennifer L. Good, CPA

Headquarters

New Haven, CT 06510, US

TRVI Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-34%

Return on Capital

-31%

Return on Assets

-25%

Earnings Yield

-2.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.01B

Shares Outstanding

141.98M

Volume

1.32M

Avg. Volume

1.51M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$49.33M

EBITDA

$42.68M

Operating Cash Flow

$42.09M

Capital Expenditure

$12.00K

Free Cash Flow

$42.10M

Cash & ST Invst.

$188.26M

Total Debt

$753.00K

Trevi Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$34.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.01B

N/A

Market Cap/Employee

$64.72M

N/A

Employees

31

N/A

Net Income

$13.19M

-27.6%

EBITDA

$14.91M

-44.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$171.10M

+67.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$364.00K

-46.5%

Short Term Debt

$318.00K

+15.2%

Return on Assets

-25.40%

N/A

Return on Invested Capital

-30.59%

N/A

Free Cash Flow

$16.79M

-24.6%

Operating Cash Flow

$16.69M

-23.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZYMEZymeworks Inc.
$25.61+1.99%
NVAXNovavax, Inc.
$9.21+2.56%
ARDXArdelyx, Inc.
$6.11-3.78%
PGENPrecigen, Inc.
$4.24-0.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
FFord Motor Company
$14.93+0.09%
AALAmerican Airlines Group
$13.85+0.02%
NIONio
$5.20-0.07%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.26+0.04%

Questions About TRVI

What is the current price of Trevi Therapeutics?

Trevi Therapeutics is trading at $14.13 per share.

What is the 52-week range for Trevi Therapeutics?

Over the past 52 weeks, Trevi Therapeutics has traded between $5.38 and $16.12.

How much debt does Trevi Therapeutics have?

As of the most recent reporting period, Trevi Therapeutics reported total debt of $682,000.

How much cash does Trevi Therapeutics have on hand?

Trevi Therapeutics reported $19.41M in cash and cash equivalents in its most recent financial results.

What is Trevi Therapeutics’s dividend yield?

Trevi Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.